Table 1 Mean live Ixodes holocyclus counts and efficacy relative to control at 48 h after treatment and after weekly re-infestations for dogs treated with a single oral dose of Simparica Trio™ or NexGard Spectra^® on Day 0

Control

 Range

17–27

16–26

22–31

20–28

19–29

18–30

 Arithmetic mean (AM)

22.13

20.63

25.38

24.50

23.50

22.75

 Geometric mean (GM)^a

21.92

20.45

25.26

24.40

23.31

22.39

Simparica Trio™

 Range

0–1

0–3

0–2

0–2

0–1

0–2

 Arithmetic mean (AM)

0.13

0.63

0.50

0.75

0.13

0.38

 AM Efficacy (%)

99.44

96.97

98.03

96.94

99.47

98.35

 Geometric mean (GM)^a

0.09

0.41

0.36

0.57

0.09

0.25

 GM Efficacy (%)

99.59

97.97

98.56

97.68

99.61

98.88

 Test statistic vs control

t₍₅₁₎= 19.75

t₍₅₁₎= 17.63

t₍₅₁₎= 19.18

t₍₅₁₎= 18.07

t₍₅₁₎= 20.13

t₍₅₁₎= 18.99

 P-value vs control

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

NexGard Spectra^®

 Range

0–1

0–5

0–4

0–7

0–1

0–4

 Arithmetic mean (AM)

0.13

1.13

1.25

1.75

0.75

1.25

 AM Efficacy (%)

99.44

94.55

95.07

92.86

96.81

94.51

 Geometric mean (GM)^a

0.09

0.71

0.78

1.10

0.68

0.91

 GM Efficacy (%)

99.59

96.54

96.92

95.48

97.08

95.92

 Test statistic vs control

t₍₄₅₎= 14.37

t₍₄₅₎= 11.95

t₍₄₅₎= 12.71

t₍₄₅₎= 11.76

t₍₄₅₎= 12.61

t₍₄₅₎= 11.82

 P-value vs control

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

 Test statistic vs sarolaner

t₍₇₃₎= 0.00

t₍₇₃₎= 0.74

t₍₇₃₎= 1.05

t₍₇₃₎= 1.17

t₍₇₃₎= 1.71

t₍₇₃₎= 1.68

 P-value vs sarolaner

1.0000

0.4599

0.2984

0.2461

0.0911

0.0972